September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding

Heghine Khachatryan/LinkedIn

Jun 29, 2026, 15:17

Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Haemophilia Foundation Australia’s post on LinkedIn, adding:

“Hemostasis is far more than the cessation of bleeding – it is a finely regulated biological equilibrium between procoagulant and anticoagulant mechanisms.

Disruption of this balance may manifest as either hemorrhagic complications or thrombotic disease, emphasizing the complexity of modern hemostasis.

Contemporary research increasingly highlights the intimate interplay between coagulation, inflammation, endothelial function, and immune responses, giving rise to the concept of immunothrombosis and reinforcing the multidisciplinary nature of thrombosis research.

These advances continue to reshape diagnostic algorithms, risk stratification, and therapeutic strategies across numerous clinical disciplines.

Continuous scientific collaboration, evidence-based practice, and translational research remain fundamental to improving outcomes for patients with bleeding and thrombotic disorders.”

Haemophilia Foundation Australia shared a post on LinkedIn:

“Currently most gene therapy for haemophilia uses gene transfer.

This involves delivering a functional gene into the body using a vector that carries it into the target cells.

This vector is often a modified virus called adeno-associated virus (AAV) made safe to use.

Once inside the body, the working gene gives instructions to liver cells to produce the missing clotting factor, which may reduce or stop bleeding episodes (‘bleeds’).

Learn more in the new Gene Therapy fact sheet.

Gene therapy is currently only available in Australia through clinical trials.

Gene therapy for haemophilia B is currently being evaluated by the Australian Government for funding to become available for Australians and we look forward to the outcome.”

Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding